Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.

@article{ermk2011EfficacyAS,
  title={Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.},
  author={Jaroslav {\vC}erm{\'a}k and Anna Jonasova and Jana Vondrakova and Lenka Walterov{\'a} and Ivana Hochov{\'a} and Magda {\vS}i{\vs}kov{\'a} and Radana Neuwirtov{\'a}},
  journal={Hemoglobin},
  year={2011},
  volume={35 3},
  pages={217-27}
}
Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 μg/L (range 825-11287 μg/L), were treated with deferiprone (L1) in a daily dose of 40-90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4-24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 μg/L in contrast to only 12 out of 26 patients with serum… CONTINUE READING